NYSE:PRGO - Perrigo Stock Price, Price Target & More

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo announced a quarterly dividend on Thursday, May 3rd. Investors of record on Friday, June 1st will be paid a dividend of $0.19 per share on Tuesday, June 19th. This represents a $0.76 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, May 31st. View Perrigo's Dividend History.

Perrigo Company PLC (NYSE:PRGO) released its quarterly earnings data on Tuesday, May, 8th. The company reported $1.26 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.12. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.21 billion. Perrigo had a return on equity of 11.93% and a net margin of 2.59%. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.05 earnings per share. View Perrigo's Earnings History.

Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Perrigo.

Perrigo updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $5.05-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.26.

17 brokerages have issued twelve-month price targets for Perrigo's shares. Their forecasts range from $79.00 to $117.00. On average, they expect Perrigo's share price to reach $93.6875 in the next twelve months. View Analyst Ratings for Perrigo.

Some companies that are related to Perrigo include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY) and Jazz Pharmaceuticals (JAZZ).

Media headlines about PRGO stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Perrigo earned a coverage optimism score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 48.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Perrigo's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.17%), Franklin Resources Inc. (5.86%), Victory Capital Management Inc. (1.75%), Clal Insurance Enterprises Holdings Ltd (1.39%), Manning & Napier Group LLC (1.23%) and Millennium Management LLC (1.02%). Company insiders that own Perrigo stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Judy L Brown, Sharon Kochan, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.

PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Migdal Insurance & Financial Holdings Ltd., Sector Gamma AS, Swiss National Bank, Millennium Management LLC, UBS Group AG, Quadrature Capital Ltd and Engineers Gate Manager LP. Company insiders that have sold Perrigo company stock in the last year include Jeffrey Needham, John Wesolowski, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Insider Buying and Selling for Perrigo.

PRGO stock was purchased by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, Clal Insurance Enterprises Holdings Ltd, Victory Capital Management Inc., New York State Common Retirement Fund, Point72 Asset Management L.P., Franklin Resources Inc., Prudential Financial Inc. and Dimensional Fund Advisors LP. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRGO stock can currently be purchased for approximately $74.36.

Perrigo has a market capitalization of $10.40 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe.

Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]